RxDoctor Payments Data

Francis Metz, MD

Internal Medicine · Morgan City, LANPI 1447257001

Payments from drug & device makers

$13,860in general payments, 2019–2025

Across 870 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Pfizer$937
  • Novo Nordisk$865
  • AstraZeneca$860
  • Johnson & Johnson$658
  • plus $7K from 53 others

What the payments were for

  • Food & beverage$13,72899%
  • Education$1321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)130$1,838
GSK87$1,279
Pfizer69$937
Novo Nordisk55$865
AstraZeneca39$860
Johnson & Johnson41$658
Merck35$527
Takeda Pharmaceuticals U.S.A., Inc.31$509
Astellas Pharma US Inc25$508
Amgen27$428
Boehringer Ingelheim28$404
Lilly USA, LLC24$377
Sanofi-aventis U.S. LLC21$323
Teva Pharmaceuticals USA, Inc.17$320
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)22$300
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$285
Ironwood Pharmaceuticals, Inc21$281
Bayer16$279
Abbott14$252
Amarin Pharma, Inc.13$223
Eisai Inc.11$215
Corium, LLC18$210
Mylan Specialty L.p.10$191
Otsuka America Pharmaceutical, Inc.8$167
Sumitomo Pharma America, Inc.6$119
Lundbeck LLC4$106
Daiichi Sankyo Inc.5$104
Phathom Pharmaceuticals, Inc.7$91
Tolmar, Inc.5$85
Biogen5$79
Dexcom, Inc.4$76
Jazz Pharmaceuticals Inc.3$72
Novartis5$71
Esperion Therapeutics, Inc.4$71
Axsome Therapeutics, Inc.4$65
Biohaven Pharmaceutical Holding Company Ltd.3$54
Urovant Sciences Inc3$51
Exact Sciences3$50
Biohaven Pharmaceuticals, Inc.3$46
Inspire Medical Systems, Inc.1$42
Verona Pharma, Inc.2$41
Smith+Nephew2$41
E.r. Squibb & Sons, L.L.C.2$37
Seqirus USA Inc2$37
Sanofi Pasteur Inc.2$28
Halozyme Inc1$24
Vanda Pharmaceuticals Inc.1$23
Alnylam Pharmaceuticals Inc.1$21
Neurocrine Biosciences, Inc.1$20
Xeris Pharmaceuticals, Inc.1$19
Hikma Pharmaceuticals USA1$18
Arbor Pharmaceuticals, Inc.1$18
Idorsia Pharmaceuticals US Inc1$18
Shire North American Group Inc1$18
Ardelyx, Inc.1$18
Boston Scientific1$17
Azurity Pharmaceuticals, Inc.1$16
Supernus Pharmaceuticals, Inc.1$15
Corcept Therapeutics1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,860 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$234,720
Medicare patients
560
Services billed
4,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide359$383,764
EliquisApixaban306$176,635
IngrezzaValbenazine Tosylate24$141,177
JardianceEmpagliflozin184$126,142
Trelegy ElliptaFluticasone/Umeclidin/Vilanter134$110,777
Synjardy XrEmpagliflozin/Metformin Hcl117$98,523
FarxigaDapagliflozin Propanediol119$84,392
XareltoRivaroxaban106$59,375
OzempicSemaglutide51$52,381
Soliqua 100-33Insulin Glargine/Lixisenatide36$41,148
EntrestoSacubitril/Valsartan48$39,077
Teriflunomide13$38,115
LinzessLinaclotide51$35,509
XifaxanRifaximin11$34,245
JanuviaSitagliptin Phosphate47$32,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$377$401,547378 claims
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Tradjenta, Combivent Respimat$404$302,173415 claims
PfizerEliquis, Abrysvo$937$188,154342 claims
GSKTrelegy Ellipta, Shingrix, Anoro Ellipta$1,279$142,997246 claims
Neurocrine Biosciences, Inc.Ingrezza$20$141,17724 claims
AstraZenecaFarxiga, Breztri Aerosphere$860$100,496144 claims
AbbVieLinzess, Vraylar$1,838$62,83266 claims
Johnson & JohnsonXarelto$658$59,375106 claims
Novo NordiskOzempic$865$52,38151 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$323$41,14836 claims
NovartisEntresto$71$39,07748 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$285$34,24511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Morgan City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →